Abstract
Mortality from prostate cancer is a large, worldwide burden and the value of population screening for prostate cancer is unknown. A consensus meeting on screening and global strategy for prostate carcinoma, held in Antwerp in 1994, resulted in a collaboration among European centres to pursue the formation of a multinational randomized screening trial. This trial is known as the “European Randomized Study of Screening for Prostate Cancer (ERSPC)”.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag France
About this paper
Cite this paper
Denis, L. (1999). Screening for Prostate Cancer: the good, the bad and the ugly. In: Hortobagyi, G.N., Khayat, D. (eds) Progress in Anti-Cancer Chemotherapy. Progress in Anti-Cancer Chemotherapy, vol 3. Springer, Paris. https://doi.org/10.1007/978-2-8178-0918-2_10
Download citation
DOI: https://doi.org/10.1007/978-2-8178-0918-2_10
Publisher Name: Springer, Paris
Print ISBN: 978-2-287-59666-7
Online ISBN: 978-2-8178-0918-2
eBook Packages: Springer Book Archive